How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension
ABSTRACT Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently in humans. Based on these properties epoprostenol, which has a short half‐life of sever...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Pulmonary Circulation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pul2.70059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063299884875776 |
|---|---|
| author | Ivan M. Robbins Anna R. Hemnes |
| author_facet | Ivan M. Robbins Anna R. Hemnes |
| author_sort | Ivan M. Robbins |
| collection | DOAJ |
| description | ABSTRACT Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently in humans. Based on these properties epoprostenol, which has a short half‐life of several minutes in vivo requiring continuous intravenous infusion, was administered to patients with pulmonary arterial hypertension (PAH) and found to decrease pulmonary vascular resistance (PVR) during acute vasodilator testing. Investigators then studied the effects of long‐term infusion of epoprostenol and observed sustained hemodynamic and clinical improvement, albeit with persistent elevation of pulmonary artery pressure and PVR. The results of a randomized multicenter study confirmed the benefit of epoprostenol, including improved survival, in patients with PAH leading to FDA approval in 1995. Before this, there was no effective therapy for the vast majority of patients with PAH. A number of other less complicated and safer medications have subsequently been approved for the treatment of patients with PAH. However, nearly 30 years after approval, despite the complexity and risks of continuous intravenous therapy, epoprostenol remains the most effective treatment for PAH. |
| format | Article |
| id | doaj-art-eafd6a9708254cdfac58994dbf98d121 |
| institution | DOAJ |
| issn | 2045-8940 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj-art-eafd6a9708254cdfac58994dbf98d1212025-08-20T02:49:40ZengWileyPulmonary Circulation2045-89402025-01-01151n/an/a10.1002/pul2.70059How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial HypertensionIvan M. Robbins0Anna R. Hemnes1Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USADivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USAABSTRACT Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently in humans. Based on these properties epoprostenol, which has a short half‐life of several minutes in vivo requiring continuous intravenous infusion, was administered to patients with pulmonary arterial hypertension (PAH) and found to decrease pulmonary vascular resistance (PVR) during acute vasodilator testing. Investigators then studied the effects of long‐term infusion of epoprostenol and observed sustained hemodynamic and clinical improvement, albeit with persistent elevation of pulmonary artery pressure and PVR. The results of a randomized multicenter study confirmed the benefit of epoprostenol, including improved survival, in patients with PAH leading to FDA approval in 1995. Before this, there was no effective therapy for the vast majority of patients with PAH. A number of other less complicated and safer medications have subsequently been approved for the treatment of patients with PAH. However, nearly 30 years after approval, despite the complexity and risks of continuous intravenous therapy, epoprostenol remains the most effective treatment for PAH.https://doi.org/10.1002/pul2.70059epoprostenolinfusionpulmonary hemodynamicstherapy |
| spellingShingle | Ivan M. Robbins Anna R. Hemnes How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension Pulmonary Circulation epoprostenol infusion pulmonary hemodynamics therapy |
| title | How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension |
| title_full | How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension |
| title_fullStr | How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension |
| title_full_unstemmed | How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension |
| title_short | How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension |
| title_sort | how a most unlikely drug changed the outcome of pulmonary arterial hypertension |
| topic | epoprostenol infusion pulmonary hemodynamics therapy |
| url | https://doi.org/10.1002/pul2.70059 |
| work_keys_str_mv | AT ivanmrobbins howamostunlikelydrugchangedtheoutcomeofpulmonaryarterialhypertension AT annarhemnes howamostunlikelydrugchangedtheoutcomeofpulmonaryarterialhypertension |